NO20066077L - Behandlingsmetode for cancer - Google Patents

Behandlingsmetode for cancer

Info

Publication number
NO20066077L
NO20066077L NO20066077A NO20066077A NO20066077L NO 20066077 L NO20066077 L NO 20066077L NO 20066077 A NO20066077 A NO 20066077A NO 20066077 A NO20066077 A NO 20066077A NO 20066077 L NO20066077 L NO 20066077L
Authority
NO
Norway
Prior art keywords
cancer
administering
relates
treating
treatment
Prior art date
Application number
NO20066077A
Other languages
English (en)
Norwegian (no)
Inventor
Mark S Berger
Iman El-Hariry
Tona Morgan Gilmer
Arundathy Nirmalini Pandite
David Rusnak
Neil L Spector
Original Assignee
Smithkline Beecham Cork Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Cork Ltd filed Critical Smithkline Beecham Cork Ltd
Publication of NO20066077L publication Critical patent/NO20066077L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20066077A 2004-06-03 2006-12-29 Behandlingsmetode for cancer NO20066077L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57682504P 2004-06-03 2004-06-03
US60679004P 2004-09-02 2004-09-02
PCT/US2005/019053 WO2005120504A2 (en) 2004-06-03 2005-06-01 Cancer treatment method

Publications (1)

Publication Number Publication Date
NO20066077L true NO20066077L (no) 2007-01-31

Family

ID=35503647

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20066077A NO20066077L (no) 2004-06-03 2006-12-29 Behandlingsmetode for cancer

Country Status (14)

Country Link
US (1) US20100063074A1 (es)
EP (1) EP1768963A4 (es)
JP (1) JP2008501690A (es)
KR (1) KR20070030240A (es)
AU (1) AU2005251722B2 (es)
BR (1) BRPI0511754A (es)
CA (1) CA2569132A1 (es)
IL (1) IL179359A0 (es)
MA (1) MA28691B1 (es)
MX (1) MXPA06013635A (es)
NO (1) NO20066077L (es)
NZ (1) NZ551622A (es)
RU (1) RU2006142420A (es)
WO (1) WO2005120504A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101594870A (zh) * 2006-08-22 2009-12-02 康塞特医药品有限公司 4-氨基喹唑啉衍生物及其使用方法
WO2009137714A2 (en) 2008-05-07 2009-11-12 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
US20100197915A1 (en) * 2008-08-06 2010-08-05 Leonid Metsger Lapatinib intermediates
EP2158912A1 (en) 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
EP2158913A1 (en) 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[(3-fluorophenyl)methoxy]phenyl]6-(5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
AU2013234921A1 (en) 2012-03-23 2014-10-02 Array Biopharma Inc. Treatment of brain cancer
US11207324B2 (en) 2017-04-28 2021-12-28 Seagen Inc. Treatment of HER2 positive cancers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
CZ300945B6 (cs) * 2000-06-30 2009-09-23 Glaxo Group Limited Zpusob prípravy 5-(6-chinazolinyl)-furan-2-karbaldehydu
EP1353693B1 (en) * 2001-01-16 2005-03-16 Glaxo Group Limited Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer
JP2004002210A (ja) * 2001-04-27 2004-01-08 Takeda Chem Ind Ltd 癌の予防・治療方法
JP2004002211A (ja) * 2001-04-27 2004-01-08 Takeda Chem Ind Ltd 癌の予防・治療方法
CA2482591A1 (en) * 2002-04-16 2003-10-30 Astrazeneca Ab Combination therapy for the treatment of cancer
WO2004000094A2 (en) * 2002-06-19 2003-12-31 Smithkline Beecham Corporation Predictive markers in cancer therapy
KR20050032110A (ko) * 2002-08-02 2005-04-06 이뮤노젠 아이엔씨 신규의 효능을 갖는 탁산을 포함하는 세포독성제 및 그치료용도
JP2004144680A (ja) * 2002-10-25 2004-05-20 Nanko Kyo 細胞増殖を制御する物質のスクリーニング方法、及びＳｐ１分子等をヌクレオリン（ｎｕｃｌｅｏｌｉｎ）分子から解離させる物質のスクリーニング方法

Also Published As

Publication number Publication date
KR20070030240A (ko) 2007-03-15
BRPI0511754A (pt) 2008-01-02
MXPA06013635A (es) 2007-02-28
JP2008501690A (ja) 2008-01-24
RU2006142420A (ru) 2008-07-20
MA28691B1 (fr) 2007-06-01
CA2569132A1 (en) 2005-12-22
AU2005251722A1 (en) 2005-12-22
NZ551622A (en) 2010-01-29
IL179359A0 (en) 2007-03-08
WO2005120504A2 (en) 2005-12-22
US20100063074A1 (en) 2010-03-11
WO2005120504A3 (en) 2006-02-23
EP1768963A4 (en) 2009-06-10
AU2005251722B2 (en) 2009-11-12
EP1768963A2 (en) 2007-04-04

Similar Documents

Publication Publication Date Title
NO20072631L (no) Kreftbehandlingsmetode
NO20066077L (no) Behandlingsmetode for cancer
NO20074366L (no) Fremgangsmate for a behandle gefitmibresistent kreft
NO20066079L (no) Behandlingsmetode for cancer
PL406680A1 (pl) Inhibitory kinaz tyrozynowych
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
EA200701302A1 (ru) 4-(n-фениламино)хиназолины/-хинолины в качестве ингибиторов тирозинкиназы
EA201691142A1 (ru) Ингибиторы мек и способы их применения
BRPI0307351B8 (pt) composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto
WO2007143483A3 (en) Combination of pazopanib and lapatinib for treating cancer
ATE552835T1 (de) Verfahren zur behandlung von tumoren mit egfr- mutationen
BR0215360A (pt) Derivados de indolina úteis como inibidores de proteìna quinase
EA200500299A1 (ru) Пиразольные композиции, используемые в качестве ингибиторов gsk-3
EA200400073A1 (ru) Пирролопиримидины как ингибиторы протеинкиназы
ATE473980T1 (de) Triazolopyridazine als proteinkinase-inhibitoren
MY144750A (en) Treatment method
ATE554087T1 (de) Neue kinaseinhibitoren
ATE493418T1 (de) Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren
NO20050528L (no) Kombinasjon av VEGF reseptor tyrosin kinase inhibitorer for behandling av kreft
EA200400674A1 (ru) Соли e-2-метокси-n-(3-(4-(3-метилпиридин-3-илокси)фениламино)хиназолин-6-ил)аллил)ацетамида, их получение и их применение против рака
NO20034204L (no) Farmasöytiske kombinasjoner til behandling av kreft
BRPI0515991A (pt) derivados de bisariluréia substituìda heterocìclica como inibidores de cinase
NO20066080L (no) Behandling med irinotecan (CPT-11) og en AGFR-inhibitor
ATE386530T1 (de) Chinazoline derivate und ihre anwendung in der krebsbehandlung
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application